Health and Global Policy Institute (HGPI)/NCD Alliance Japan held the Second Advisory Board Meeting of the “Project for Considering the Future of Precision Medicine with Industry, Government, Academia, and Civil Society.” To avoid the potential spread of Coronavirus Disease 2019 (COVID-19), the meeting was held in a fully remote format and was closed to the public.

At the meeting, participants discussed the directions of solutions for the five discussion points identified at the first advisory board meeting (held December 14, 2021), which are listed below.

1. Equity in the healthcare provision system and in access
2. Building patient awareness and mechanisms for solving Ethical, Legal, and Social Issues (ESIs) and expanding Patient and Public Involvement (PPI)
3. Assessment methods suitable for precision medicine
4. Building systems for promoting R&D and making effective use of evidence
5. Limits on the number of times insurance coverage is granted, limits on the timing for insurance coverage, and how to best provide testing and treatment

Moving forward, we will draft and publicize policy recommendations based on the discussions held at the first and second advisory board meetings as well as on the multifaceted opinions we gathered from multi-stakeholders from industry, Government, academia, and civil society during individual hearings. These efforts will be advanced mainly at HGPI.

■ Event overview
Date and time: Tuesday, February 22, 2022; from 13:00 to 15:00
Venue: Online using the Zoom conferencing system
Host: Health and Global Policy Institute (HGPI)

■ Second Advisory Board Meeting participants (Titles omitted; in no particular order)
Ataru Igarashi (Associate Professor, Unit of Public health and Preventive Medicine, Yokohama City University School of Medicine)
Mitsuho Imai (Project Assistant Professor, Shinanomachi Cancer Center, School of Medicine, Keio University)
Hiroji Iwata (Vice Director and Chief, Department of Breast Oncology, Aichi Cancer Center Hospital)
Atsushi Otsu (Director, National Cancer Center Hospital East)
Shinji Kosugi (Professor, Medical Ethics and Medical Genetics, Department of Social Medicine, Graduate School of Medicine and Faculty of Medicine, Kyoto University)
Naomi Sakurai (President, Cancer Solutions Co., Ltd)
Kuniko Sunami (Department of Laboratory Medicine, National Cancer Center Hospital)
Kazuo Hasegawa (Representative, NPO Lung Cancer Patient Association One Step)
Yoshiyuki Majima (Chairman, NPO PanCAN Japan)
Tetsuya Mitsutomi (Professor/Senior Staff, Division of Thoracic Surgery, School of Medicine, Kindai University)
Takayuki Yoshino (Director, Department of Gastrointestinal Oncology, National Cancer Center Hospital East)
Reiko Akizuki (Director, Oncology Department, Medical Affairs Division, Janssen Pharmaceutical K.K.)
Kosuke Iijima (Head, Foundation Medicine Business Department, Chugai Pharmaceutical Co., Ltd.)
Sotaro Enatsu (General Manager, Oncology Business Unit, Research and Development and Medical Affairs, Eli Lilly Japan K.K.)
Junpei Soeda (Head, Japan Medical Affairs, Japan Oncology Business Unit, Takeda Pharmaceutical Company Limited)